International Journal of Infectious Diseases
Volume 14, Issue 10 , Pages e852-e856 , October 2010

Clinical and economic burden of pneumonia among adults in Latin America

  • Raul E. Isturiz

      Affiliations

    • Department of Medicine, Centro Médico de Caracas and Centro Médico Docente La Trinidad, Edificio Anexo A, Sótano 3, San Bernardino, Caracas 1011, Venezuela
    • Corresponding Author InformationCorresponding author. Tel.: +58 212 551 7889; fax: +58 212 552 0626.
    • ,
  • Carlos M. Luna

      Affiliations

    • Pulmonary Medicine Division, Hospital de Clínicas, Universidad de Buenos Aires, Argentina
    • ,
  • Julio Ramirez

      Affiliations

    • Division of Infectious Diseases, University of Louisville, Louisville, Kentucky, USA

Received 10 June 2009 ,Revised 19 August 2009 ,Accepted 25 February 2010.

References 

  1. World Health Organization. The global burden of disease: 2004 update. Geneva, Switzerland: World Health Organization; 2008.
  2. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269–1276
  3. Pan American Health Organization. The ten leading causes of death in countries of the Americas. 2006 ed. Washington, DC: PAHO; 2006.
  4. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56:1–120
  5. United Nations. World population prospects: the 2006 revision. Report No. ST/ESA/SER.A/261/ES. New York, NY: United Nations; 2007.
  6. United Nations. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. New York, NY: United Nations; 2009. Available at: http://unstats.un.org/unsd/methods/m49/m49regin.htm. (accessed February 13, 2009).
  7. Ramirez JA; Community-Acquired Pneumonia Organization (CAPO) Investigators. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO International Cohort Study. Semin Respir Crit Care Med 2005; 26:543-52.
  8. Gabastou JM, Agudelo CI, de Cunto Brandileone MC, Castañeda E, Silva de Lemos AP, Di Fabio JL SIREVA II Laboratory Group. [Characterization of invasive isolates of S. pneumoniae, H. influenzae and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000-2005]. Rev Panam Salud Publica. 2008;24:1–14
  9. Arnold FW, Summersgill JT, LaJoie AS, Peyrani P, Marrie TJ, Rossi P, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175:1086–1093
  10. Luna CM, Famiglietti A, Absi R, Videla AJ, Nogueira FJ, Fuenzalida AD, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest. 2000;118:1344–1354
  11. Diaz A, Barria P, Niederman M, Restrepo MI, Dreyse J, Fuentes G, et al. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest. 2007;131:779–787
  12. Jardim JR, Rico G, de la Roza C, Obispo E, Urueta J, Wolff M, et al. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial]. Arch Bronconeumol. 2003;39:387–393
  13. Caberlotto OJ, Cadario ME, Garay JE, Copacastro CA, Cabo A, Savy VL. [Community-acquired pneumonia in patients from two different hospitals]. Medicina (B Aires). 2003;63:1–8
  14. Valdivia GC. [Epidemiology of community-acquired pneumonia in adults]. Rev Chil Infect. 2005;22(Suppl 1):S11–S17
  15. Sociedad Brasileira de Pneumologia e Tisologia. Consenso brasileiro de pneumonias em individuos adultos imunocompetentes. [Part 1: Community-acquired pneumonia (CAP)]. J Pneumologia 2001; 27(Suppl 1):S3-21.
  16. Franca SA, Carvalho CRR. Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study. Braz J Infect Dis. 2002;6:157–163
  17. Ministério da Saúde. DATASUS—Departamento de Informática do SUS. Available at: http://www.datasus.gov.br. (accessed September 26, 2008).
  18. Diretriz para pneumonias adquiridas na comunidade (PAC) em adultos imunocompetentes. J Bras Pneumol 2004; 30(Suppl 4):S1-24.
  19. Christensen D, Luna CM, Martinez J, Rodriguez E, Marzoratti L, Gonzalez J, et al. [Adherence with national guidelines in hospitalized patients with community-acquired pneumonia: results of the CAPO study in Argentina]. Medicina (B Aires). 2007;67(6 pt 2):709–713
  20. Moore P, Ortega JP, Saldias F, Oyarzun MA. [Ambulatory management of community-acquired pneumonia in the elderly]. Rev Med Chil. 2006;134:1568–1575
  21. Saldias FP, Mardonez JM, Marchesse MR, Viviani PG, Farias GG, Diaz AF. [Prognostic factors and outcome of community-acquired pneumonia in hospitalized adult patients]. Rev Med Chil. 2002;130:1373–1382
  22. Saldias PF, O’Brien SA, Gederlini GA, Farias GG, Diaz FA. [Community-acquired pneumonia requiring hospitalization in immunocompetent elderly patients: clinical features, prognostic factors and treatment]. Arch Bronconeumol. 2003;39:333–340
  23. Brandileone MC, Casagrande ST, Guerra ML, Zanella RC, de Andrade AL, Di Fabio JL. Increase in penicillin resistance of invasive Streptococcus pneumoniae in Brazil after 1999. J Antimicrob Chemother. 2005;56:437–439
  24. Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program. Clin Microbiol Infect. 2004;10:645–651
  25. Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98). Braz J Infect Dis. 2000;4:245–254
  26. Informe Regional de SIREVA II: datos por pais y por grupos de edad sobre las caracteristicas de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores, 2000-2005. Report No.: THS/EV – 2007/002.: Organizacion Panamericana de la Salud; 2007.
  27. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–1754
  28. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31:383–421
  29. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Eighteenth informational supplement. CLSI document M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
  30. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis. 2009;48:1596–1600
  31. Constenla D. Evaluating the costs of pneumococcal disease in selected Latin American countries. Rev Panam Salud Publica. 2007;22:268–278
  32. Centers for Disease Control and Prevention., Pneumococcal disease. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S, editors. Epidemiology and prevention of vaccine-preventable diseases. 10th ed. Washington, DC: Public Health Foundation; 2008.
  33. World Health Organization., Pneumococcal conjugate vaccine for childhood immunization—WHO position paper. Wkly Epidemiol Rec 2007; 82:93-104.
  34. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46(RR-8):1–20.
  35. Di Fabio JL, de Quadros C. Considerations for combination vaccine development and use in the developing world. Clin Infect Dis. 2001;33(Suppl 4):S340–S345
  36. Centers for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine—worldwide, 2000-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1148-51.
  37. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737–1746
  38. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005; 54:893-7.

PII: S1201-9712(10)02397-0

doi: 10.1016/j.ijid.2010.02.2262

International Journal of Infectious Diseases
Volume 14, Issue 10 , Pages e852-e856 , October 2010

Article Tools

* Image Usage & Resolution